About

/About
About 2017-09-21T07:35:51+00:00

Lantern’s Core Operational Strength

  • Precision.

  • Speed.

  • Cost Effective.

  • Technology and Data Driven.

Lantern Pharma is reinventing the cancer drug development process by tailoring multiple promising precision drug programs to the right cancer patients using advanced genomics and artificial intelligence (AI) with significantly reduced cost and time. Lantern has in-licensed, validated, de-risked clinical stage drugs that are discontinued for development. Lantern identifies genetic signatures or molecular markers for the patient response to the drug and further validates by conducting small, focused phase 2 clinical trials to greatly increase the value of each drug, thereby creating multiple exit points for each drug.

Technology

RADR V 3.0™ – Integrated Data Analytics, Experimental Biology and Machine Learning based Platform for Patient Genetic Profiling for Drug Response Prediction.

Meet Our Team

Strong scientific and business team with expertise in pharmaceutical development.

Management Team

Arun K Asaithambi,Co-founder, CEO
Dr. Arun Asaithambi is CEO of Dallas based Lantern Pharma Inc, Genomics & AI-based biotech company developing precision cancer drugs that he co-founded with Dr. Peter Nara and Dr. Greg Tobin during late 2013.
Gregory Tobin,Chief Science Officer
Dr. Tobin’s primary research interests include the development of vaccines, immunotherapeutics, and small molecules for the treatment of cancer.
Jeff Thomas,Chief Operating Officer
Mr. Thomas has been actively engaged with Lantern Pharma for the past 2 and half years and has served as COO since March 2017. Prior joining Lantern his 25+ year career included senior-level positions in sectors including public accounting, entertainment, and private investment.
Peter Nara,Chief Business Officer
Dr. Nara is the President and Chairman of the Board of Biological Mimetics have 18 years of experience in successful co-founding and developing the discovery biotechnology company.

Scientific and Strategic Advisor

Jean Phillipe Vert
Dave Copps
Panna Sharma
Anand Asaithambi
Arul Chinnaiyan
Vasant Honavar
Alex Treece
Jim Montgomery